Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.

scientific article published on 08 May 2015

Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S10637-015-0246-2
P8608Fatcat IDrelease_uqq4h33smrgjdnrs6xu7wncwyy
P932PMC publication ID4905857
P698PubMed publication ID25952464

P50authorKatrina S PedersenQ87264362
Charles ErlichmanQ107069384
P2093author name stringRobert R McWilliams
Nathan R Foster
George P Kim
Andrea Wang-Gillam
P2860cites workA pathway of multi-chaperone interactions common to diverse regulatory proteins: estrogen receptor, Fes tyrosine kinase, heat shock transcription factor Hsf1, and the aryl hydrocarbon receptorQ24627720
Nonparametric Estimation from Incomplete ObservationsQ25938997
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinomaQ28300339
Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cellsQ28368209
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialQ29547565
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineQ29616728
Steroid receptor interactions with heat shock protein and immunophilin chaperonesQ29619628
Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumorsQ33163062
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumorsQ33387877
Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directionsQ34314706
A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignanciesQ34636437
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemiaQ35528633
The Stress Response: Implications for the Clinical Development of Hsp90 InhibitorsQ35551875
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinomaQ35691439
Cisplatin abrogates the geldanamycin-induced heat shock responseQ36948038
Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival.Q40380713
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.Q40614350
Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stressQ40624388
Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreasQ40661394
Geldanamycin restores a defective heat shock response in vivoQ40778294
Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activityQ41139893
Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents.Q42492406
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumorsQ44893938
Frequent activation of AKT2 kinase in human pancreatic carcinomasQ47251291
Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivativesQ71751283
Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulationsQ84587884
P433issue4
P921main subjecttanespimycinQ4552288
pancreatic cancerQ212961
phase II clinical trialQ42824440
P304page(s)963-968
P577publication date2015-05-08
P1433published inInvestigational New DrugsQ2312231
P1476titlePhase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study
P478volume33

Reverse relations

cites work (P2860)
Q4119799717AAG-induced internalisation of HER2-specific Affibody molecules
Q92358243A Long Non-coding RNA Lnc712 Regulates Breast Cancer Cell Proliferation
Q92404317Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma
Q28075606Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents
Q90293459Novel insights into molecular chaperone regulation of ribonucleotide reductase
Q38648236Realistic biological approaches for improving thermoradiotherapy.
Q52655041Sensitization of multidrug-resistant cancer cells to Hsp90 inhibitors by NSAIDs-induced apoptotic and autophagic cell death.
Q33688577Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
Q42317467TNF induced cleavage of HSP90 by cathepsin D potentiates apoptotic cell death
Q52716432Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery.
Q92463715The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview

Search more.